WAYNE, Pa. & MISGAV, Israel--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on January 2, 2014, the Company granted options to subscribe for 15,000 shares of the Company’s common stock, par value US$0.0001 (“Common Shares”) (“Options”) and made a restricted share award of 7,000 Common Shares (“Restricted Shares”) to each of Sol Barer, Isaac Blech, Alastair Clemow, Wilbur “Bill” Gantz, Joseph Grano, Jr., Joel Kanter, Stephen McMurray, and Andrew Pearlman, all non-executive directors of the Company, as part of their remuneration for the year.
Help employers find you! Check out all the jobs and post your resume.
